read time 9 mins
Welcome to the Carbon Newsletter!
This update keeps you informed about the latest happenings at the gym and provides insights to help you build a high-performing, healthy lifestyle.
Today at a Glance
- Peptides Aren't Magic. They're Signals. — The signals your body stopped sending
- New Women's Strength Class - Starting May 26th
- Carbon Training Centre Anniversary Party - Tacos and Tequila
- Call for Volunteers - Carbon One - Health Intelligence Platform
Peptides Aren't Magic. They're Signals.
Here's what no one tells you about the peptide conversation happening right now.
It's not really about peptides. It's about signaling.
When the body's own communication infrastructure starts to degrade, can you restore the communication it's stopped sending itself?
That's the actual story. The rest is noise.
Your body runs on signals.
Every process — fat metabolism, tissue repair, sleep architecture, immune response, hormonal output — is coordinated by molecular messengers telling your cells what to do, when to do it, and when to stop.
Peptides are those messengers.
Short chains of amino acids. Precise. Targeted. Already present in your body by the thousands.
The peptides being discussed in clinical and biohacking circles aren't foreign substances. They're analogs of what your body already makes — the synthesized version of the same molecular language your cells use to communicate.
Which means the real question isn't "should I take peptides?"
It's…
What signals has your system stopped sending — and why?
What Peptides Actually Do - And Why the Framing Matters
Your body doesn't just run on energy. It runs on governed energy.
That distinction matters more than most people realize.
Every time your cells generate ATP — every contraction, every repair cycle, every metabolic process — the system produces chemical byproducts that need to be managed. Reactive intermediates. Electron pressure. Inflammatory signals. Heat.
The question is never just "can the body produce energy?" It's whether the infrastructure governing that process can keep pace.
Peptides operate at the level of that governance infrastructure.
They don't add fuel. They modulate signaling — adjusting how your body prioritizes repair, how aggressively it recruits growth hormone, how efficiently it manages blood sugar, and how well it resolves inflammation.
Think of it less like adding horsepower and more like upgrading the operating system.
The Landscape: Where the Evidence Is - and Isn't
Let's be direct about what we know.
The GLP-1 class (semaglutide, tirzepatide) has the strongest clinical foundation of anything in this space. These compounds don't just suppress appetite — they work on vagal nerve signaling, slow gastric emptying, and improve insulin sensitivity in ways that genuinely shift metabolic governance. The results in clinical trials are substantive. These are FDA-approved and well-studied.
But the research that gets less airtime is what happens when you train on them.
Slowed gastric emptying means slower glucose delivery. In a hard training session — anything at threshold or above — will create a meaningful mismatch between demand and supply.
Blood sugar drops. Glycogen availability tanks. Performance degrades in ways that feel like fitness problems but are actually a fueling problem.
The muscle mass data is harder to ignore. GLP-1 agonists produce significant lean mass loss alongside fat loss — in some trial populations, a substantial portion of total weight lost comes from muscle.
For a sedentary population managing metabolic disease, that tradeoff may be acceptable.
For anyone who trains seriously, it's a problem worth thinking through before committing to a protocol. Resistance training and adequate protein intake mitigate it, but don't eliminate it.
This is where retatrutide becomes an interesting conversation. Where semaglutide targets one receptor (GLP-1) and tirzepatide targets two (GLP-1 and GIP), retatrutide is a triple agonist — GLP-1, GIP, and glucagon receptor. The glucagon component adds meaningful fat oxidation signaling that the dual agonists don't have.
Early trial data suggest superior fat loss with potentially better body composition outcomes.
It's not yet approved, and the long-term picture isn't fully written. But for an athletic population where lean mass preservation matters, the mechanism is more aligned with the goal than standard GLP-1 protocols.
The GLP-1 class is powerful. It's also a tool that requires context. Metabolic governance without performance governance will leave many struggling.
Growth hormone secretagogues (CJC-1295 + Ipamorelin, Sermorelin) support the body's own GH release rather than flooding the system with exogenous hormone.
The distinction matters.
You're not adding GH — you're restoring the pulsatile signaling your body lost. For body recomposition, recovery, and sleep architecture, this is a meaningful difference from traditional HGH protocols.
BPC-157 and TB-500 are where it gets interesting — and where intellectual honesty is required.
BPC-157 (Body Protective Compound) appears to accelerate tissue repair, modulate gut lining integrity, and influence tendon and ligament healing through multiple mechanisms. TB-500 works on actin regulation — the structural protein involved in cell migration and wound repair. Both show strong results in animal models and have a long anecdotal track record in athletic and clinical populations.
But the human trial data is thin.
That doesn't mean they don't work. It means the mechanism is plausible, the user reports are consistent, and the human research hasn't caught up yet.
For some people in specific contexts, that's a reasonable calculated decision. For others, it's not. Know which one you are.
The longevity stack (MOTS-c, Epitalon, Thymosin Alpha-1, GHK-Cu) is operating at a different level. These compounds target mitochondrial function, telomere support, immune modulation, and anti-inflammatory signaling — all things that degrade with age and chronic stress.
MOTS-c in particular is worth understanding. It's encoded in mitochondrial DNA — not nuclear DNA — and functions as a regulator of mitochondrial stress response. When cells are under metabolic load, MOTS-c helps maintain electron transport chain function and activates AMPK, the cellular energy sensor. For anyone focused on performance and longevity, this is one of the more mechanistically compelling compounds in this space.
It also comes with a red flag we've observed in some clients: histamine responses. Flushing, itching, or a general sense of systemic activation — sometimes within minutes of injection. This isn't universal, and it doesn't necessarily mean the compound is wrong for that person. But it does suggest underlying mast cell sensitivity that deserves attention before continuing.
If you're someone who already reacts to foods, environmental triggers, or other injectable compounds, this is worth knowing before you dose. Start low. Watch the response. The histamine reaction itself is useful information about your immune system.
Epitalon supports sleep architecture and melatonin production through pineal gland signaling. GHK-Cu is a copper-binding peptide with broad anti-inflammatory and wound-healing properties. These aren't hype — they're targeted interventions for systems that genuinely degrade under chronic stress.
The Regulatory Situation in 2026 — What's Actually Changing
This matters more than most people realize right now.
In 2023, the FDA placed a long list of popular peptides — BPC-157, TB-500, CJC-1295, Ipamorelin, Epitalon, Semax, MOTS-c, and others — into a category that effectively blocked traditional compounding pharmacies from producing them. The stated concern: immunogenicity, purity, insufficient safety data.
The practical result: most access moved into the gray market. And gray market peptide quality is genuinely variable. Some products test well below labeled purity. The compound you think you're taking may not be what you're actually taking.
That's not a hypothetical concern. It's a documented one.
Here's what changed in April 2026: The FDA removed 12 of these peptides from the restricted category after the original nominators withdrew their concerns. A Pharmacy Compounding Advisory Committee meeting is scheduled for July 23–24, 2026 to formally review seven key peptides — BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon — for potential inclusion on the official compounding list.
This doesn't make them FDA-approved drugs.
But it does signal a meaningful regulatory thaw. If these compounds make the compounding list, access to pharmaceutical-grade versions through legitimate pharmacies becomes significantly cleaner. That's a real difference for anyone who's been sourcing in the gray market and wondering about what they're actually getting.
A second group goes under review in early 2027.
Watch the July meeting. The outcome will shape how accessible quality peptides are for the next several years.
What This Isn't
Before you start pricing out protocols, a few things worth naming directly.
Peptides don't fix a broken foundation.
If your sleep is poor, your training load is unmanaged, your nutrition is inconsistent, and your recovery is an afterthought — peptides will not compensate for that. The signaling infrastructure they're modulating needs something to work with.
Governance tools only matter if there's a system worth governing.
Exogenous signaling isn't free.
One of the under-appreciated risks of regular exogenous peptide use is receptor down regulation. If you're consistently flooding receptors with signals the body would normally produce in a pulsatile, context-dependent pattern, you risk blunting the body's own production.
This is the same dynamic we see with antioxidant megadosing: you don't just eliminate the problem, you eliminate the signal. Work with a clinician who understands cycling protocols and how to preserve endogenous function.
Sourcing is not a minor detail.
Gray market peptides aren't just legally ambiguous — they're biologically variable. Until the regulatory picture clarifies, sourcing through a licensed compounding pharmacy under medical supervision is the only context where you can have confidence in what you're actually taking.
The Bottom Line
Peptides are not a category to dismiss.
They're also not a shortcut.
For the right person, in the right context, with the right clinical oversight, they represent some of the most targeted signaling tools available in modern personalized medicine.
The goal isn't to add more signals. It's to restore the ones your system has stopped generating efficiently.
That requires bloodwork. It requires a clinician who actually reads it. It requires understanding what your system is doing before you decide what it needs.
That's the work.
Women's Strength Class
We're adding a Women's Strength class to the weekly schedule because of the high demand — and because barbell training, done with intention, changes the baseline everything else sits on.
The class is barbell-based. Primary movements — squat, hinge, press, pull — progressed over time with coaching built into every session. Not a circuit. Not a rotation of trendy exercises. A structured approach to building strength that compounds week over week.
All levels. You don't need a background in lifting to show up. You need to show up.
Women's Strength Every Tuesday — 4:30 PM Starting May 26th
Look for it on the schedule if you already have a membership, or email hello@carbontc.co for more info.
Carbon Training Centre - Anniversary Party
One Year.
A year ago, Carbon opened its doors with a clear idea of what health and performance care should look like. Everything since then has been building towards it.
That work is ongoing. But one year in, it's worth stopping to acknowledge what's been built — the clients, the community, the outcomes that don't show up on a spreadsheet.
We're celebrating with the people who made it worth celebrating.
Tacos & Tequila — Carbon Training Centre Anniversary Party May 23 @ 5 PM
We'll be handing out the first-ever Carbies — Carbon's yearly member awards. Mada gets credit for the name. The recognition belongs to you.
Look for the invites. Come hungry. Come ready to celebrate. One year down.
Carbon One - We're Looking for 10 People
This isn't a study. It's not a survey. It's the early build of something that doesn't exist yet.
Carbon One is a health intelligence platform — designed to take your data and turn it into something actionable. Not a dashboard of numbers. A system that learns, responds, and compounds over time.
We're onboarding 10 people to help us build it.
Here's what we need from you:
Bloodwork in the last 3 months.
A Garmin for sleep and HRV tracking.
And a willingness to share that data for platform monitoring.
Daily check-ins will be sent to you. They take 15 to 20 seconds. That data compiles. Over time, you stop getting generic feedback and start getting feedback that's actually about you.
As new features roll out, you help steer the direction. You're not a beta tester. You're a co-author of what this becomes.
Bonus points if you have — or are interested in — full genomic sequencing. And if the idea of agentic connectivity to a health platform genuinely excites you rather than confuses you, you're probably exactly who we're looking for.
Ten spots. If you think that's you, reach out directly.
Davis@carbontc.co
Lovely Meal Prep
This is a local, fresh, organic meal-prep service all of us coaches use. We can't stress how convenient and wonderful it is. If you haven't met Korynn yet, she is a Carbon client and the owner of Lovely Meal Prep. You can catch her lifting ALL the weights on Mondays and Wednesdays with either Mada or Madeline.
Korynn is offering 20% off your first order with code: carbon20.
Ordering happens weekly on Wednesdays HERE.
Pick-up is Monday or Tuesday inside the Carbon fridge.
Be well,
Unsubscribe | Update your profile |
